ArticleBiomedical reports2026

Integrated transcriptomic and molecular docking analysis identifies Rhotekin 2 as a promising therapeutic target for overcoming gemcitabine resistance in cholangiocarcinoma.

Sonexai Kidoikhammouan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.